一、临床肿瘤杂志（2023年第73卷第4期）

July/August 2023 - Volume 73 - Issue 34（2023年7/8月第73卷第4期）
https://acsjournals.onlinelibrary.wiley.com/toc/15424863/2023/73/4

PERSPECTIVES（观点）
1. 临床医师需要关注多重用药问题
(Clinicians need to stay current with polypharmacy concerns)
作者：Mike Fillon

二、柳叶刀（2023年第402卷第10395-10399期）

（一）01 July 2023 - Volume 402 - Issue 10395（2023年7月1日第402卷第10395期）
https://www.thelancet.com/journals/lancet/issue/vol402no10395/PIIS0140-6736(23)X0026-9

COMMENT（评论）
1. 对于复发性流产和遗传性易栓症的女性，是时候终止为其开具常规低分子肝素处方了
(Time to stop routine prescription of low-molecular-weight heparin to women with recurrent pregnancy loss and inherited thrombophilia)
作者：Annika Strandell* (Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden)

ARTICLES（文章）
2.在难治性转移性结直肠癌 （FRESCO-2） 患者中，呋喹替尼与安慰剂的比较：一项国际性、多中心、随机、双盲、3期研究
(Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study)
作者：Arvind Dasari* (Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center,USA)

3.肝素治疗女性复发性流产和遗传性易栓症（ALIFE2）：一项国际开放标签、随机对照试验
(Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial)
作者：Siobhan Quenby, Saskia Middeldorp (Division of Biomedical Sciences, Warwick Medical School, University of Warwick,UK; Department of Internal Medicine, Radboud University Medical Center, Netherlands)

（二）08 July 2023 - Volume 402 - Issue 10396（2023年7月8日第402卷第10396期）
https://www.thelancet.com/journals/lancet/issue/vol402no10396/PIIS0140-6736(23)X0027-0 

COMMENT（评论）
1.自行鼻内给药用以终止室上性心动过速
(Self-administered intranasal medication to terminate supraventricular tachycardia)
作者：Timothy Campbell,Saurabh Kumar* (Department of Cardiology, Westmead Hospital, Australia)

CORRESPONDENCE（通信）
2.通过抗体检测预测免疫功能低下人群的COVID-19感染风险
(Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing)
作者：Ratna Wijaya, Sean H Lim* (Centre for Cancer Immunology, University of Southampton, UK)

ARTICLES（文章）
3.使用症状提示的重复给药方案自行给药依曲帕米用于治疗房室结依赖性室上性心动过速 （RAPID）：一项多中心，随机试验
(Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial)
作者：Bruce S Stambler, A John Camm* (Cardiac Arrhythmia Research and Education, Piedmont Heart Institute, USA; Clinical Cardiology, St George's University of London, UK)

（三）15 July 2023 - Volume 402 - Issue 10397（2023年7月15日第402卷第10397期）
https://www.thelancet.com/journals/lancet/issue/vol402no10397/PIIS0140-6736(23)X0028-2 

COMMENT（评论）
1.肾细胞癌的测序检查点抑制剂治疗
(Sequencing checkpoint inhibitor therapy in renal cell carcinoma)
作者：Kathryn E Beckermann, Brian I Rini* (Vanderbilt Ingram Cancer Center Nashville, USA)

2.充装有大剂量双抗生素的骨水泥在半关节成形术患者中的应用
(High-dose dual-antibiotic loaded bone cement in patients undergoing hemiarthroplasty)
作者：Saad Tarabichi, Javad Parvizi* (Rothman Orthopaedic Institute at Thomas Jefferson University, USA)

CORRESPONDENCE（通信）
3.IMmotion010在罕见肾癌组织学中的价值
(The value of IMmotion010 for rare kidney cancer histologies)
作者：Giovanni Maria Iannantuono, Andrea B Apolo* (Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, USA)

4.IMmotion010在罕见肾癌组织学中的价值——作者回复
(The value of IMmotion010 for rare kidney cancer histologies – Authors' reply)
作者：Robert Uzzo, Sumanta K Pal* (Department of Urology, Fox Chase Cancer Center Philadelphia, USA; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, USA)

ARTICLES（文章）
5.在既往免疫检查点抑制剂治疗（CONTACT-03）后进展的肾细胞癌患者中，联合使用阿替利珠单抗与卡博替尼对比单用卡博替尼：一项多中心、随机、开放标签的 3 期试验
(Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial)
作者：Sumanta Kumar Pal,Toni K Choueiri* (Department of Medical Oncology, City of Hope Comprehensive Cancer Center, USA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, USA)

6.在英国，充装有大剂量双抗生素的骨水泥在髋关节置换术中的应用（WHiTE 8）：一项随机对照试验
(High-dose dual-antibiotic loaded cement for hip hemiarthroplasty in the UK (WHiTE 8): a randomised controlled trial)
作者：Nickil R Agni, Matthew L Costa* (Northumbria Healthcare NHS Foundation Trust, Trauma and Orthopaedics, UK; Oxford Trauma and Emergency Care, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, Kadoorie Centre, University of Oxford, UK)

CLINICAL PICTURE（临床表现）
7.接受地舒单抗治疗的巨细胞瘤患儿干骺端硬化
(Metaphyseal sclerosis in a child with a giant cell tumour treated with denosumab)
作者：Vivian Szymczuk* (Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, USA)

（四）22 July 2023 - Volume 402 - Issue 10398（2023年7月22日第402卷第10398期）
https://www.thelancet.com/journals/lancet/issue/vol402no10398/PIIS0140-6736(23)X0029-4 

COMMENT（评论）
1.下一代激素疗法联合PARP抑制治疗转移性去势抵抗性前列腺癌
(Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer)
作者：Wassim Abida* (Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, USA)

2.随机试验显示阿片类药物缓解急性背痛的效果并不强于安慰剂
(Randomised trial reveals opioids relieve acute back pain no better than placebo)
作者：Mark D Sullivan* (Department of Psychiatry and Behavioral Sciences, University of Washington, USA)

3.抗生素耐药性细菌在反复发生的大规模聚集事件中的全球化
(Globalisation of antibiotic-resistant bacteria at recurring mass gathering events)
作者：Avinash Sharma* (Department of Biotechnology National Centre for Cell Science, NCCS Complex, India)

ARTICLES（文章）
4.他拉唑帕利联合恩扎卢胺治疗一线转移性去势抵抗性前列腺癌 （TALAPRO-2） ：一项随机、安慰剂对照的3期试验
(Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial)
作者：Neeraj Agarwal* (Huntsman Cancer Institute, University of Utah, USA)

5.阿片类镇痛药治疗急性腰痛和颈部疼痛（OPAL 试验）：一项随机安慰剂对照试验
(Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial)
作者：Caitlin M P Jones, Chung-Wei Christine Lin* (Sydney Musculoskeletal Health, Faculty of Medicine and Health, The University of Sydney, Australia)

（五）29 July 2023 - Volume 402 - Issue 10399（2023年7月29日第402卷第10399期）
https://www.thelancet.com/journals/lancet/issue/vol402no10399/PIIS0140-6736(23)X0030-0 

 COMMENT（评论）
1.我们是否准备好在低风险骨髓增生异常综合征中引入新的前期治疗?
(Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes?)
作者：Hetty E Carraway (Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, USA)

ARTICLES（文章）
2.罗特西普与依泊汀α治疗未使用红细胞生成刺激剂、输血依赖、低危骨髓增生异常综合征(COMMANDS)的疗效和安全性比较：一项3期、开放标签、随机对照试验的中期分析
(Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial)
作者：Uwe Platzbecker (Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Germany)

三、新英格兰医学杂志（2023年7月第389卷第1-4期）

（一）6 July 2023 - Volume 389 - No 1（2023年7月6日第389卷第1期）
https://www.nejm.org/toc/nejm/389/1 

ORIGINAL ARTICLES（原创文章）
1.布乐韦肽治疗慢性丁型肝炎的3期随机试验
(A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D)
作者：Heiner Wedemeyer* (the Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Germany)

2.慢性淋巴细胞白血病使用共价BTK抑制剂效果不佳后，可用Pirtobrutinib
(Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia)
作者：Anthony R. Mato, Jennifer A. Woyach* (Memorial Sloan Kettering Cancer Center; the Ohio University Comprehensive Cancer Center, Columbus)

EDITORIALS（社论）
3.抑制性BTK在慢性淋巴细胞白血病中的应用
(Inhibiting BTK in Chronic Lymphocytic Leukemia)
作者：Arnon P. Kater (the Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam,The Netherlands)

CORRESPONDENCE（通信）
4.芬太尼过量用药导致院外死亡
(Fentanyl-Associated Overdose Deaths Outside the Hospital)
作者：Molly M. Jeffery

（二）13 July 2023 - Volume 389 - No 2（2023年7月13日第389卷第2期）
https://www.nejm.org/toc/nejm/389/2 

ORIGINAL ARTICLES（原创文章）
1.睾酮替代疗法的心血管安全性
(Cardiovascular Safety of Testosterone-Replacement Therapy)
作者：A. Michael Lincoff¹, Shalender Bhasin², Steven E. Nissen¹* (1. Department of Cardiovascular Medicine, Cleveland Clinic, USA; 2. the Research Program in Men’s Health: Aging and Metabolism, Brigham and Women’s Hospital, Harvard Medical School, USA)

2.BRAF-MEK抑制剂用于治疗新诊断的乳头状颅咽管瘤
(BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas)
作者：Fred G. Barker,Evanthia Galanis* (Massachusetts General Hospital Cancer Center, Harvard Medical School, USA; Mayo Clinic, USA)

3.入院前使用氨甲环酸治疗严重创伤
(Prehospital Tranexamic Acid for Severe Trauma)
作者：Russell L. Gruen* (the Office of the Dean, College of Health and Medicine, the Australian National University, Australia)

4.奥希替尼在切除EGFR突变NSCLC的患者中的总生存期
(Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC)
作者：Masahiro Tsuboi*, Roy S. Herbst* (the National Cancer Center Hospital East, Japan; the Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, USA)

EDITORIALS（社论）
5.老年男性睾酮替代疗法的安全性
(Safety of Testosterone-Replacement Therapy in Older Men)
作者：Eric Orwoll (Oregon Health and Science University, Portland)

6.创伤患者使用氨甲环酸 — 在挽救更多生命的同时，需慎重考虑后果
(Tranexamic Acid for Trauma Patients — More Lives to Save and Outcomes to Consider)
作者：Haleema Shakur-Still (the Global Health Trials Group, Clinical Trials Unit, London School of Hygiene and Tropical Medicine, UK)

CORRESPONDENCE（通信）
7.使用芦可替尼或贝舒地尔治疗后的皮肤鳞状细胞癌
(Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil)
作者：Gun Ho Lee, Chrysalyne D. Schmults* (Massachusetts General Hospital, USA; Brigham and Women’s Hospital, USA)

8.转移性结直肠癌的三线治疗
(Third-Line Therapy in Metastatic Colorectal Cancer)

9. 医护人员可用BCG预防 Covid-19
(BCG to Protect against Covid-19 in Health Care Workers)
作者：Guillermo H. Lopez-Campos* (Queen’s University Belfast, UK)

（三）20 July 2023 - Volume 389 - No 3（2023年7月20日第389卷第3期）
https://www.nejm.org/toc/nejm/389/3 

ORIGINAL ARTICLES（原创文章）
1.度普利尤单抗用于嗜酸性粒细胞计数提示的COPD伴2型炎症
(Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts)
作者：Surya P. Bhatt*, Klaus F. Rabe (the Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Germany; LungenClinic Grosshansdorf and Christian Albrechts University of Kiel, Germany)

2.母婴接种婴儿B组链球菌疫苗的潜能
(Potential for Maternally Administered Vaccine for Infant Group B Streptococcus)
作者：Shabir A. Madhi,Annaliesa S. Anderson* (the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit,South Africa; Vaccine Research and Development, Pfizer, USA) 

3.齐贝司兰，一种治疗高血压的RNA干扰剂
(Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension)
作者：Akshay S. Desai* (Division of Cardiovascular Medicine, Brigham and Women’s Hospital, USA)

4.抗体NI006消耗心脏转甲状腺素淀粉样蛋白的1期试验
(Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid)
作者：Peter C. Kahr¹, Thibaud Damy², Pablo Garcia-Pavia³* (1. Alexion–AstraZeneca Rare Disease, Boston (M.F.M.); and Neurimmune , Switzerland; 2. the Cardiology Department and French National Reference Center for Cardiac Amyloidosis, France; 3. the Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Spain)

EDITORIALS（社论）
5.慢性阻塞性肺病的生物制剂——终于来了
(Biologics for COPD — Finally Here)
作者：Alvar Agusti (Cátedra de Salud Respiratoria, University of Barcelona, Spain)

6.B组链球菌疫苗 — Sisyphus 协调
(Group B Streptococcal Vaccine — Sisyphus Reconciled)
作者：Carol J. Baker (the Infectious Diseases Division, Department of Pediatrics, McGovern Medical School, University of Texas Health Science Center, USA)

CORRESPONDENCE（通信）
7.阿奇霉素用于预防阴道分娩女性的脓毒症或死亡
(Azithromycin to Prevent Sepsis or Death in Women Planning a Vaginal Birth) 

8.抗击Covid-19的BNT162b2疫苗研究中，潜在的“健康疫苗受试者偏倚”
(Potential “Healthy Vaccinee Bias” in a Study of BNT162b2 Vaccine against Covid-19)
作者：Tracy B. Høeg (University of California, USA)

9.暴露后多西环素治疗性传播感染
(Postexposure Doxycycline for Sexually Transmitted Infections)

（四）27 July 2023 - Volume 389 - No 4（2023年7月27日第389卷第4期）
https://www.nejm.org/toc/nejm/389/4 

ORIGINAL ARTICLES（原创文章）
1.既往未使用过胰岛素的2型糖尿病患者每周使用Icodec胰岛素与每日使用甘精胰岛素U100的比较
(Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin)
作者：Julio Rosenstock* ( Velocity Clinical Research at Medical City, USA)

2.口服Orexin受体2激动剂治疗1型发作性嗜睡症
(Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1)
作者：Yves Dauvilliers¹, Emmanuel Mignot², Giuseppe Plazzi³, Christian von Hehn⁴* (1. Sleep and Wake Disorders Center, Department of Neurology, Gui de Chauliac Hospital, and the University of Montpellier, INSERM Institute for Neurosciences of Montpellier , France; the Stanford Department of Psychiatry and Behavioral Sciences, Center for Sleep Sciences and Medicine, Stanford University Medical School, USA; 3. IRCCS, Istituto delle Scienze Neurologiche di Bologna, Italy; 4. Takeda Development Center Americas, USA)

3.局部晚期直肠癌的术前治疗
(Preoperative Treatment of Locally Advanced Rectal Cancer)
作者：Deborah Schrag (Department of Medicine, Memorial Sloan Kettering Cancer Center, USA)

4.来那度胺难治性多发性骨髓瘤的Cilta-cel或标准疗法
(Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma)
作者：Jesús San-Miguel ( Clínica Universidad de Navarra, Spain)

CORRESPONDENCE（通信）
5.Peresolimab治疗成人类风湿关节炎的2期试验
(Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis)

四、美国医学会杂志（2023年7月第330卷第1-4期）

（一）3 July 2023 -Volume 330 - No.1（2023年7月3日第330卷第1期）
https://jamanetwork.com/journals/jama/issue/330/1 

Original Investigation（原始调查）
1.来特莫韦与缬更昔洛韦预防高危肾移植受者巨细胞病毒：一项随机临床试验
(Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial)
作者：Ajit P. Limaye (Division of Allergy & Infectious Diseases, Departments of Medicine & Laboratory Medicine and Pathology, University of Washington Medicine, USA)

Editorial（社论）
2.预防肾移植后巨细胞病毒的抗病毒新选择
(A New Antiviral Option for Cytomegalovirus Prevention After Kidney Transplant)
作者：Zoe Raglow, Daniel R. Kaul* (University of Michigan Medical School, USA)

（二）11 July 2023 -Volume 330 - No.2（2023年7月11日第330卷第2期）
https://jamanetwork.com/journals/jama/issue/330/2 

Original Investigation（原始调查）
1.贝培酸用于他汀类药物不耐受患者的心血管事件一级预防
(Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients)
作者：Steven E. Nisse (Cleveland Clinic, Cleveland, Ohio)

2.脓毒症危重患者连续与间歇使用美罗培南：MERCY随机临床试验
(Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial)
作者：Giacomo Monti(Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Italy)

3.金花碱可用于戒烟：一项随机临床试验
(Cytisinicline for Smoking Cessation: A Randomized Clinical Trial)
作者：Nancy A. Rigotti (Tobacco Research and Treatment Center, Division of General Internal Medicine and Mongan Institute, Department of Medicine, Massachusetts General Hospital, Harvard Medical School,USA)

Research Letter（研究信）
4.在英格兰，BA.1的二价 COVID-19 疫苗使用和中风之间的联系
(BA.1 Bivalent COVID-19 Vaccine Use and Stroke in England)
作者：Nick Andrews (Immunisation Division, UK Health Security Agency, UK)

Editorial（社论）
5.贝培酸用于心血管疾病高风险一级预防：不作为他汀类药物的替代，而是一个不错的备选方案
(Bempedoic Acid for High-Risk Primary Prevention of Cardiovascular Disease: Not a Statin Substitute but a Good Plan B)
作者：Dhruv S. Kazi (Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, USA)

6.长期输注β-内酰胺类抗生素能否改善危重脓毒症患者的预后？
(Do Prolonged Infusions of β-Lactam Antibiotics Improve Outcomes in Critically Ill Patients With Sepsis?)
作者：Claire N. Shappell (Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA)

Medical News in Brief（医学新闻简讯）
7.入院前氨甲环酸不能改善残疾结局
(Prehospital Tranexamic Acid Does Not Improve Disability Outcomes)
作者：Emily Harris

Comment & Response（评论与回复）
8.分娩时使用阿奇霉素与安慰剂治疗新生儿败血症的比较
(Intrapartum Azithromycin vs Placebo for Neonatal Sepsis)
作者：Wan-Jie Gu (Department of Intensive Care Unit, First Affiliated Hospital of Jinan University, China)

9.分娩时使用阿奇霉素与安慰剂治疗新生儿败血症的比较——作者回复
(Intrapartum Azithromycin vs Placebo for Neonatal Sepsis—Reply)
作者：Anna Roca (MRC Unit The Gambia, London School of Hygiene and Tropical Medicine, The Gambia)

（三）18 July 2023 -Volume 330 - No.3（2023年7月18日第330卷第3期）
https://jamanetwork.com/journals/jama/issue/330/3 

Original Investigation（原始调查）
1. 2 型糖尿病成年患者初始胰岛素治疗，每周一次Icodec胰岛素 与每日一次德谷胰岛素对比：ONWARDS 3 随机临床试验
(Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial)
作者：Ildiko Lingvay (Division of Endocrinology, Department of Internal Medicine and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, USA)

Medical News in Brief（医学新闻简讯）
2.阿司匹林每日剂量与老年人贫血之间的联系
(Daily Dose of Aspirin Linked With Anemia in Older People)
作者：Emily Harris

3.睾酮治疗未见增加主要心血管事件
(Testosterone Therapy Did Not Increase Major Cardiovascular Events)
作者：Emily Harris

（四）25 July 2023 -Volume 330 - No.4（2023年7月25日第330卷第4期）
https://jamanetwork.com/journals/jama/issue/330/4

Original Investigation（原始调查）
1.阿巴西普、塞尼韦洛或英夫利西单抗用于治疗COVID-19成人住院患者：一项随机临床试验
(Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial)
作者：Jane A. O’Halloran (Washington University St Louis, USA)

2.识别可能受益于抗生素治疗急性鼻窦炎的儿童：一项随机临床试验
(Identifying Children Likely to Benefit From Antibiotics for Acute Sinusitis: A Randomized Clinical Trial)
作者：Nader Shaikh (Department of Pediatrics, University of Pittsburgh School of Medicine, UPMC Children’s Hospital of Pittsburgh, USA)

Medical News & Perspectives（医学新闻与展望）
3.今秋 COVID-19 疫苗将针对 Omicron XBB 亚变异株，但适应人群尚未可知
(This Fall’s COVID-19 Vaccines Will Target Omicron XBB Subvariants, but Who Needs Them Remains to Be Seen)
作者：Rita Rubin

Medical News in Brief（医学新闻简讯）
4.三激素复方Retatrutide可使体重减轻24%
(Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss)
作者：Emily Harris

5.FDA批准口服恩格列净用于儿童糖尿病
(Oral Empagliflozin Receives FDA Approval for Children With Diabetes)
作者：Emily Harris

Comment & Response（评论与回复）
6.异位妊娠风险和左炔诺孕酮宫内缓释系统
(Ectopic Pregnancy Risk and Levonorgestrel-Releasing Intrauterine Systems)
作者：Sebastian Jugl (Department of Pharmaceutical Outcomes and Policy, University of Florida, USA)

7.异位妊娠风险和左炔诺孕酮宫内缓释系统——作者回复
(Ectopic Pregnancy Risk and Levonorgestrel-Releasing Intrauterine Systems—Reply)
作者：Amani Meaidi (Cancer Surveillance and Pharmacoepidemiology, The Danish Cancer Society Research Center, Denmark)

8.维拉帕米与儿童1型糖尿病的胰岛β细胞功能
(Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes)
作者：Nin-Chieh Hsu (Taipei City Hospital Zhongxing Branch, National Taiwan University College of Medicine, China)

9.维拉帕米与儿童1型糖尿病的胰岛β细胞功能——作者回复
(Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes—Reply)
作者：Gregory P. Forlenza (Barbara Davis Center, University of Colorado Anschutz Medical Campus, USA)

五、自然：药物发现综述（2023年7月第22卷第7期）

（一）July 2023 - Volume 22 - Issue 7（2023年7月第22卷第7期）
https://www.nature.com/nrd/volumes/22/issues/7 

News & Analysis（新闻与分析）
1. RSV疫苗获得具有里程碑意义的FDA批准
(RSV vaccines score landmark FDA approvals)
作者：Katie Kingwell

News in Brief（新闻简讯）
2.FDA批准首款用于潮热的NK3受体拮抗剂
(FDA approves first-in-class NK3 receptor antagonist for hot flushes)
作者：Asher Mullard

3.PD1激动剂抗体通过治疗自身免疫性疾病的首项II期试验
(PD1 agonist antibody passes first phase II trial for autoimmune disease)
作者：Asher Mullard 

4.FDA批准首个局部基因疗法
(FDA approves first topical gene therapy)
作者：Asher Mullard

5.FDA批准用于治疗耐药性肺炎的新抗生素组合
(FDA approves new antibiotic combination for drug-resistant pneumonia)
作者：Asher Mullard

Research Highlights（研究亮点）
6.ROS介导的抗癌药物耐药途径
(A ROS-mediated resistance pathway to anticancer drugs)
作者：Alex Eccleston

7.通过与SERT对接发现了新的抑制剂
(Docking on SERT reveals new inhibitors)
作者：M. Teresa Villanueva

8.PI3K激活剂开启重建途径
(PI3K activator taps route to regeneration)
作者：Katie Kingwell

9.一种治疗鲍曼不动杆菌的新抗生素
(A new antibiotic for A. baumannii)
作者：Sarah Crunkhorn

10.用双特异性抗体优化白血病治疗
(Improving leukaemia treatment with bispecific antibodies)
作者：Sarah Crunkhorn

Reviews（评论）
11.氘在药物研发中的应用：进展、机遇和挑战
(Deuterium in drug discovery: progress, opportunities and challenges)
作者：Rita Maria Concetta Di Martino, Tracey Pirali* (Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Italy)

Perspectives（观点）
12.加速抗病毒药物发现：COVID-19的经验教训
(Accelerating antiviral drug discovery: lessons from COVID-19)
作者：Annette von Delft*, Alpha A. Lee* (Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, UK; PostEra, Inc., USA)

六、自然：免疫学综述（2023年7月第23卷第7期）

July 2023 - Volume 23 - Issue 7 （2023年7月第23卷第7期）
https://www.nature.com/nri/volumes/23/issues/7

Research Highlight（研究亮点）
1. 联合EZH2抑制和诱导衰老有助于免疫细胞对抗胰腺癌
(Combining EZH2 inhibition with senescence induction helps immune cells fight pancreatic cancer)
作者：Yvonne Bordon*

2. 肿瘤靶向TNF联合化疗在胶质母细胞瘤中展现良好效果
(Combination of tumour-targeted TNF and chemotherapy shows promising results in glioblastoma)
作者：Alexandra Flemming*

In Brief（简述）
3. 用于治疗胰腺癌的mRNA疫苗
(mRNA vaccine for treating pancreatic cancer)
作者：Lucy Bird*

七、柳叶刀：呼吸医学（2023年7月）

July 2023 - Volume 11 - Number 7 （2023年7月第11卷第7期）
https://www.thelancet.com/journals/lanres/issue/vol11no7/PIIS2213-2600(23)X0007-1 

1.雾化Ad5-nCoV、肌内注射Ad5-nCoV或灭活COVID-19疫苗CoronaVac接种后，作为第二剂加强剂的安全性和免疫原性：一项多中心，开放标签，4期，随机试验
(Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial)
作者：Rong Tang¹, Hui Zheng², Bu-Sen Wang³, Jin-Bo Gou⁴, Li-Hua Hou⁴*, Feng-Cai Zhu¹*, Jing-Xin Li⁵* (1. NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, China; 2. School of Public Health, Southeast University, China; 3. Beijing Institute of Biotechnology, Academy of Military Medical Sciences, China;4.Tianjin CanSino Biotechnology, China; 5. School of Public Health, Nanjing Medical University, China)

2. EGFR突变非鳞状非小细胞肺癌患者使用EGFR酪氨酸激酶抑制剂治疗 (ORIENT-31)后，采用信迪利单抗联合化疗的疾病进展：来自双盲，随机，安慰剂对照，3期试验的第二次中期分析
(Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial)
作者：Shun Lu* (Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, China)

八、英国医学期刊（2023年7月第382卷第8389-8393期）

（一）01 July 2023 - Volume 382 - Issue 8389（2023年7月1日第382卷第8389期）
https://www.bmj.com/content/382/8389 

Research（研究）
1. 维生素D补充剂与主要心血管事件：D-Health随机对照试验
(Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial)
作者：Bridie Thompson, Rachel E Neale* (Population Health Program, QIMR Berghofer Medical Research Institute, Australia)

2. 更年期激素治疗与痴呆症：全国性的嵌套病例对照研究
(Menopausal hormone therapy and dementia: nationwide, nested case-control study)
作者：Nelsan Pourhadi* (Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Denmark)

Editorials（社论）
3. 更年期的激素治疗和痴呆症
(Menopausal hormone therapy and dementia)
作者：Kejal Kantarci* (Department of Radiology, Division of Neuroradiology, Mayo Clinic Rochester, USA)

（二）08 July 2023 - Volume 382 - Issue 8390（2023年7月8日第382卷第8390期）
https://www.bmj.com/content/382/8390 

略

（三）15 July 2023 - Volume 382 - Issue 8391（2023年7月15日第382卷第8391期）
https://www.bmj.com/content/382/8391 

略

（四）22 July 2023 - Volume 382 - Issue 8392（2023年7月22日第382卷第8392期）
https://www.bmj.com/content/382/8392 

News（新闻）
1. 研究发现，Donanemab可适度减缓阿尔茨海默氏症的进展
(Donanemab leads to modest slowing of Alzheimer’s progression, study finds)
作者：Gareth Iacobucci

Education（教育）
2. 肝素诱导的皮肤坏死
(Heparin induced skin necrosis)
作者：Emeka B Kesieme, Keith G Buchan* (Department of Cardiothoracic Surgery, Aberdeen Royal Infirmary, UK)

（五）29 July 2023 - Volume 382 - Issue 8393（2023年7月29日第382卷第8393期）
https://www.bmj.com/content/382/8393 

Research（研究）
1. 北欧国家奥密克戎占主导地位期间，针对重症covid-19异源第三剂疫苗接种方案的效果比较：基于人群的队列分析
(Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses)
作者：Niklas Worm Andersson* (Department of Epidemiology Research, Statens Serum Institut, Denmark)

2. BA.4-5或BA.1二价mRNA加强疫苗的安全性：全国性队列研究
(Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study)
作者：Niklas Worm Andersson* (Department of Epidemiology Research, Statens Serum Institut, Denmark)

3. 北欧国家50岁以上成人接种二价BA.4-5和BA.1 mRNA加强疫苗的效果比较：全国队列研究
(Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study)
作者：Niklas Worm Andersson* (Department of Epidemiology Research, Statens Serum Institut, Denmark)

Education（教育）
4. 辅助阴道分娩：有撕裂或手术切口的女性需要及时使用抗生素
(Assisted vaginal births: women who tear or have a surgical cut need prompt antibiotics)
作者：Helen Saul(NIHR Evidence, UK)

九、自然：医学（2023年7月第29卷第7期）

July 2023 - Volume 29 - Issue 7（2023年7月第29卷第7期）
https://www.nature.com/nm/volumes/29/issues/7 

NEWS（新闻）
1.首个获批的口腔粪菌移植疗法
(First oral fecal microbiota transplant therapy approved)
作者：Thiago Carvalho (Portugal)

News Feature（新闻专题）
2.如何对抗抗生素耐药性
(How to fight antibiotic resistance)
作者：Mike May (Freelance writer and editor, USA)

Article（文章）
3.CD19 CAR T细胞疗法和预防性使用安纳白介素治疗复发或难治性淋巴瘤：2 期试验中期结果
(CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results)
作者：Jae H. Park*, Karthik Nath (Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA)

4.生物标志物指导、基于帕博利珠单抗的联合疗法治疗非小细胞肺癌：2期KEYNOTE-495/KeyImPaCT试验中期结果
(Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results)
作者：Martin Gutierrez*, Roy S. Herbst* (Hackensack University Medical Center,USA; Yale Cancer Center, Yale School of Medicine, USA)

5.帕博利珠单抗在不同组织学脑转移瘤中的应用：2期试验结果
(Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results)
作者：Priscilla K. Brastianos*, Albert E. Kim (Massachusetts General Hospital Cancer Center, Harvard Medical School, USA) 

6.免疫抑制性疾病患者接种COVID-2疫苗后，SARS-CoV-19特异性免疫反应和临床结果
(SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease)
作者：Eleanor Barnes¹, Carl S. Goodyear², Michelle Willicombe³, Charlotte Gaskell⁴, David Thomas³, Pamela Kearns⁴, Amanda Kirkham⁴, Iain B. McInnes²* (1.Nuffield Department of Medicine, University of Oxford, UK; 2. College of Medical, Veterinary & Life Sciences, University of Glasgow, UK; 3. Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, UK; 4. Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, UK)

7.FGF21类似物聚乙二醇胺在重度高甘油三酯血症中的应用：一项随机2期试验
(The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial)
作者：Deepak L. Bhatt* (Mount Sinai Heart, Icahn School of Medicine, Mount Sinai Health System, USA)

十、世界精神病学（2023年第22卷第2期）

（一）2023 - Volume 22 - Issue 2（2023年第22卷第2期）
https://onlinelibrary.wiley.com/toc/20515545/2023/22/2

略